Treatment Patterns Among Patients With Prostate Cancer Prior to Diagnosis of a Castration-resistant State

A Retrospective Observational Study to Describe Treatment Patterns Among Patients With Prostate Cancer Prior to Diagnosis of a Castration-resistant State, in Routine Clinical Practice in Spain.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01560858

Enrollment

407

Registered

2012-03-22

Start date

2012-04-30

Completion date

2013-05-31

Last updated

2019-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Brief summary

The purpose of the protocol is to describe treatment patterns among patients with prostate cancer prior to diagnosis of castration-resistant state.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥ 18 years * Patients with prostate cancer who had developed a castration resistant state in the last 24 months prior to starting the study * Patient must give written informed consent before any study related procedure

Exclusion criteria

* Patients with medical histories lacking data required to evaluate the study objectives

Design outcomes

Primary

Measure	Time frame	Description
Prior treatment before progression to advanced or metastatic disease.	Baseline	Number of participants with each category of treatment.
Treatment of advanced or metastatic disease.	Baseline	Number of participants with each category of treatment.

Secondary

Measure	Time frame	Description
Clinical management of Castration-Resistant Prostate Cancer (CRPC) patients in the clinical practice.	Baseline	Percentage of specialists (urologist, radiotherapist, oncologist or other specialist) in charge of treatment decision in CRPC patients.
Number of CRPC patients with signs and symptoms of metastatic disease.	Baseline	—
Time to castration resistant state after beginning of hormonotherapy.	Baseline	—
Demographic data.	Baseline	—

Countries

Spain

Outcome results